lobbying_filings_raw: c19ebd7a-203f-4a56-aab0-8b794c28ca5a
This data as json
| filing_uuid | filing_type | registrant_id | registrant_name | client_id | client_name | filing_year | filing_period | received_date | amount_reported | is_amendment | is_no_activity | is_termination | raw_json | registrant_state | registrant_country | registrant_house_id | client_state | client_ppb_state | client_country | client_ppb_country | client_general_description | client_government_entity | affiliated_org_count | client_entity_id | client_government_unit_id | client_match_method | client_match_confidence |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| c19ebd7a-203f-4a56-aab0-8b794c28ca5a | Q3 | 40036301 | KNIGHT CAPITOL CONSULTANTS | 210713 | REGENXBIO | 2022 | third_quarter | 2022-10-17T17:55:53-04:00 | 60000.0 | 0 | 0 | 0 | {"url": "https://lda.senate.gov/api/v1/filings/c19ebd7a-203f-4a56-aab0-8b794c28ca5a/", "filing_uuid": "c19ebd7a-203f-4a56-aab0-8b794c28ca5a", "filing_type": "Q3", "filing_type_display": "3rd Quarter - Report", "filing_year": 2022, "filing_period": "third_quarter", "filing_period_display": "3rd Quarter (July 1 - Sep 30)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/c19ebd7a-203f-4a56-aab0-8b794c28ca5a/print/", "filing_document_content_type": "text/html", "income": "60000.00", "expenses": null, "expenses_method": null, "expenses_method_display": null, "posted_by_name": "Patricia Knight", "dt_posted": "2022-10-17T17:55:53-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "1701 Pennsylvania Avenue, NW", "registrant_address_2": "Suite 900", "registrant_different_address": false, "registrant_city": "Washington,", "registrant_state": "DC", "registrant_zip": "20006", "registrant": {"id": 40036301, "url": "https://lda.senate.gov/api/v1/registrants/40036301/", "house_registrant_id": 39935, "name": "KNIGHT CAPITOL CONSULTANTS", "description": "Government Relations", "address_1": "817 North Lincoln Street", "address_2": null, "address_3": null, "address_4": null, "city": "Arlington", "state": "VA", "state_display": "Virginia", "zip": "22201", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "PATRICIA KNIGHT", "contact_telephone": "+1 202-510-5264", "dt_updated": "2026-03-04T13:51:53.437656-05:00"}, "client": {"id": 210713, "url": "https://lda.senate.gov/api/v1/clients/210713/", "client_id": 125, "name": "REGENXBIO", "general_description": "Develop innovative therapies to treat patients with rare or otherwise debilitating disease", "client_government_entity": false, "client_self_select": null, "state": "MD", "state_display": "Maryland", "country": "US", "country_display": "United States of America", "ppb_state": "MD", "ppb_state_display": "Maryland", "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2021-05-03"}, "lobbying_activities": [{"general_issue_code": "HCR", "general_issue_code_display": "Health Issues", "description": "Potential legislation implementing value based purchasing for pharmaceuticals (HR 7389); Possible provisions related to Drug Pricing Legislation that affect biological products' development, approval, accelerated approval, and marketing, including deliberations associated with the Reauthorization of the Prescription Drug User Fee Act ( HR 7667) (S 4348), or the continuing resolution(Further Extendjnf Government Funding Act P.L. 117-70. Possible drug pricing legislation included in any budget reconciliation legislation ( no specific number). Reauthorization of the Newborn Screening Saves Lives Act (HR 482, S 350.)", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 40329, "prefix": null, "prefix_display": null, "first_name": "PATRICIA", "nickname": null, "middle_name": null, "last_name": "KNIGHT", "suffix": null, "suffix_display": null}, "covered_position": "Chief of Staff, Senator Orrin G. Hatch; Health Policy Director - Senator Orrin Hatch", "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "MMM", "general_issue_code_display": "Medicare/Medicaid", "description": "Inclusion of provisions affecting the reimbursement of gene therapies that may be contained in any drug pricing legislation or budget legislation (H.R. 3 or its successor; the Build Back Better Act (HR 5376)/or any successor reconciliation bill. Development of Value Based Purchasing legislation ( HR 7389).", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 40329, "prefix": null, "prefix_display": null, "first_name": "PATRICIA", "nickname": null, "middle_name": null, "last_name": "KNIGHT", "suffix": null, "suffix_display": null}, "covered_position": "Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch", "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "PHA", "general_issue_code_display": "Pharmacy", "description": "Possible legislation which may affect Food and Drug Administration review of biologic products (no specific bill)", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 40329, "prefix": null, "prefix_display": null, "first_name": "PATRICIA", "nickname": null, "middle_name": null, "last_name": "KNIGHT", "suffix": null, "suffix_display": null}, "covered_position": "Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch", "new": false}], "government_entities": [{"id": 1, "name": "SENATE"}]}, {"general_issue_code": "TAX", "general_issue_code_display": "Taxation/Internal Revenue Code", "description": "Potential changes in the corporate tax rate or other provisions of interest to business (Build Back Better Act, H.R. 5376 or any successor budget reconciliation legislation).", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 40329, "prefix": null, "prefix_display": null, "first_name": "PATRICIA", "nickname": null, "middle_name": null, "last_name": "KNIGHT", "suffix": null, "suffix_display": null}, "covered_position": "Chief of Staff, Senator Orrin Hatch; Health Policy Director, Senator Orrin Hatch.", "new": false}], "government_entities": [{"id": 1, "name": "SENATE"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} | VA | US | 39935 | MD | MD | US | US | Develop innovative therapies to treat patients with rare or otherwise debilitating disease | 0 | 0 | 4263 | normalized_name | 0.7 |